FDA approval of two new drugs for idiopathic pulmonary fibrosis (Esbriet and Ofev) offers new hope for patients who live with this deadly, incurable disease. The U.S. Food and Drug Administration has approved Esbriet (pirfenidone), a TGF-beta synthesis inhibitor for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Esbriet is a medication that is used to treat a lung disease known as idiopathic pulmonary fibrosis (IPF). This condition is a fatal disease that causes the progression of the scarring of the lung, making breathing difficult for patients with this condition. Eventually, the lung will harden and stop functioning altogether. There is no cure for the disease. This medication is available in tablet form only.